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The cellular composition of bone marrow  
Bone marrow is a spongy tissue present within the central cavity of many large bones of the body 
that has been shown to perform many important regenerative functions. There are two types of 
bone marrow: red marrow and yellow marrow. Hematopoiesis, the process of generating blood cells 
takes place in the hematopoietic tissue of the red marrow, and so, unsurprisingly, all mature blood 
cell types, with the exception of lymphocytes, are found to be present in this fraction, along with the 
numerous blood progenitors, including hematopoietic stem cells. The stroma of the bone marrow 
contains the yellow marrow, and consists of all tissues that are not related to hematopoiesis. This 
includes blood vessels called sinusoids, as well as adipocytes, osteoblasts and connective fibroblasts.  
Bone marrow is generally considered to contain two distinct stem cell systems: CD45-positive 
hematopoietic stem cells, HSC, and CD45-negative mesenchymal stem cells, MSC; of which HSCs are 
the more abundant and the better understood cell type [1]. HSCs are a multipotent population of 
cells that express markers including the hematopoietic marker CD45 as well as CD34, CD133 and 
CD117. MSCs are a more complex cell type that reside in the stroma of the bone marrow, as well as 
in other tissues and organs such as adipose tissue [2] and notably umbilical cord blood [3]. In mice 
they have even been located in more obscure areas such as the liver, kidneys and lungs [4]. They 
express markers such as Stro-1, CD90 and CD106 but are CD34-, CD45- and CD133-negative [5], 
although no consensus over a complete and unique set of identifying markers currently exists [1], 
largely because of conflicting reports over their potency, but are also characterised by their 
fibroblast-like morphology (see Figure 1). Initially MSCs were believed to be purely osteogenic [6] 
but were later shown to be a multipotent cell type capable of differentiating into connective tissue 
cells such as osteoblasts, adipocytes and chondrocytes [7,8]. However, more recent findings have led 
research groups to hypothesise that they could be very “plastic”; capable of differentiating into a 
greater number of different cell types including cardiomyocytes [9], neural cells [10,11]  and  
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endothelial cells [8]. It is thought that MSCs and HSCs are interrelated because secreted cytokines 
from one group have been shown to affect the differentiation pathway taken by the other [12]. 
 
Figure 1 - A light microscope image showing the typical size and morphology of human MSCs. 
Other stem/progenitor cell types have also been identified in bone marrow which may be linked to 
HSCs and MSCs or may explain their perceived capacity for multilineage differentiation. Examples 
include endothelial progenitor cells, EPC, also known as angioblasts, which are another resident 
bone marrow stem cell type that has been shown to circulate in peripheral blood and contribute to 
regeneration; in this case particularly of vascular tissue in damaged organs such as the pancreas, 
lung and heart [13]. Multipotent adult progenitor cells, MAPC, are another cell type, reported by 
several groups to be capable of differentiating into the three germ layers: endoderm, mesoderm and 
ectoderm [14,15,16], but are unable to differentiate into hematopoietic cells. This is in contrast to 
the so-called “pluripotent stem cells” (PSC) which are able to do so, despite lacking the CD45 
hematopoietic marker. CXCR4-positive “very small embryonic/epiblast-like”, VSEL, stem cells have 
since been identified as another pluripotent stem cell-type in murine bone marrow [17] and human 
umbilical cord blood [18]. These were initially thought to be CXCR4-positive “tissue committed stem 
cells”, TCSC [5], and it is hypothesised that these are a dormant sub-population of PSCs which may 
participate in hematopoiesis and the turnover of monopotent progenitors [19]. TCSCs, or VSEL stem 
cells, may also play a role in regenerating damaged tissues or organs as they were shown to respond 
to the presence of SDF-1 [20], HGF and LIF [21]; all of which have been shown to be released by 
damaged tissue, and SDF-1 in particular is secreted by bone marrow fibroblasts. It is also considered 
that VSEL cells may be more likely to turn cancerous if exposed to mutagenic substances [19]. VSEL 
stem cells have also been shown to be more abundant in the bone marrow of younger donors, and 
have consequently been considered to play some part in the ageing process, along with telomere 
shortening which is known to result from stem cell division [22]. It is thought that the actions of 
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these cells may previously have been mistakenly attributed to the perceived plasticity of HSCs or 
MSCs [5,22]. 
Why isolate MSC populations? 
Ultimately, the goal of stem cell research is to produce therapeutic treatments which can restore or 
establish a normal function to damaged tissues or organs [23]. These treatments will be produced 
through the expansion and differentiation of human stem cells, and can be either allogeneic or 
autologous in nature. Allogeneic treatments involve the use of cells obtained from a donor, which is 
beneficial to the patient as, ideally, only one medical procedure would be required to implant the 
therapeutic product. However, in many cases this type of therapy would also require the use of 
immuno-suppressive drugs in order to combat the possibility of immune rejection of the 
transplanted cells. This complication might not always occur with stem cell therapies, however, 
because evidence suggests that some populations, including MSCs [24], and embryonic stem cells 
[25], may be immune-privileged, although this has been strongly disputed more recently [26,27]. 
Autologous therapies, where the patients themselves are the donors, do not carry the risk of 
immune rejection, but do require an additional procedure to surgically extract the required cells for 
the treatment. Another problem with this method is that the quality of the extracted stem cell 
samples from bone marrow is, to some degree, related to the age of the patient [22], leading to 
variability in the outcomes of the treatments. 
Due largely to their due to the multipotent differentiation capacity, MSCs derived from bone marrow 
are thought to be highly promising, not only for use in stem cell therapies, but also as tools in 
research, either with the goal of discovering a novel stem cell-based therapeutic treatment or for 
generating a source of clinically relevant cells which can act as a model for small-scale, in vitro drug 
testing. The requirements of instruments and techniques used for separating MSCs from bone 
marrow for research purposes will naturally be quite different from those used for producing a stem 
cell therapy. For example, in therapeutic production it is usually essential for separation systems to 
be capable of high throughput and a high yield. Following the isolation of MSCs from bone marrow, 
an expansion protocol would require a certain number of cells to satisfy a minimum seeding density 
so as to ensure the cells are able to survive and proliferate in a healthy state. It is estimated that 
between 109 and 1010 of these cells would be required for many cell therapies [28], and it is usually 
desirable to create a bank of frozen cells for each patient, particularly in the case of autologous 
therapies, so that the treatment can be re-applied if necessary. Hence, being able to extract the 
maximum yield of MSCs from a given bone marrow sample could dramatically reduce the waiting 
time for the patient and significantly improve the chances of a positive outcome from the treatment. 
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Conversely, instruments for research purposes are not likely to be required to handle large volumes, 
and maximising the yield of MSCs, although desirable, might not be so vital for the often relatively 
small scale expansion processes. Similarly, while maintaining sterility is clearly very important in 
both cases, if a contamination occurs in research, the impact in terms of time and costs is usually 
minimal because the work generally takes place at a lower scale. The worst case scenario is perhaps 
that erroneous results are obtained, if the infection is not detected. On the other hand, in the case 
of therapeutic production, the results of an undetected infection can of course be disastrous, 
highlighting the need for stringent quality controls. This should never occur, however, because any 
separation technique for therapeutic production must conform to Good Manufacturing Practice 
standards, which should ensure that the instruments used are demonstrably capable of reproducible 
quality and sterility in the final product. 
Separation Techniques 
Initial purification of bone marrow aspirate 
Human bone marrow is most commonly extracted from the posterior iliac crest under local 
anaesthetic. The initial sample should be around 0.3mL in volume, as attempts to draw out more 
marrow will cause the sample to be diluted with peripheral blood. The syringe used to perform the 
biopsy will have been prefilled with a sodium heparin anticoagulant solution [29] which will dilute 
the sample significantly in any case. This technique is clearly very prone to operator variability which 
is evident by the fact it is recommended that the samples should be checked during the biopsy to 
ensure the presence of marrow particles, called “spicules” [29]. Therefore, in addition to the natural, 
largely age-related, variability that will occur with bone marrow samples [22], the quality of the 
sampling technique will cause further inconsistencies, and the MSC population will differ in size as a 
result. 
MSCs are thought to account for only 1 in 105-106 bone marrow cells [30], but will be a far greater 
proportion of the adherent population. Therefore the first step when attempting to isolate them is 
often to exploit their adherent properties by suspending the bone marrow aspirate in a tissue 
culture-treated plastic flask [6,31]. This technique filters out the non-adherent cells, such as the 
hematopoietic cells, which do make up a relatively large portion of the bone marrow, and, 
depending on the bone marrow sample size, may be necessary to increase the quantity of desired 
cells in the sample, as additional purification steps can leave only 103-104 cells in some cases [30]. 
This can then be followed by additional purification steps because even the adherent fraction of cells 
from bone marrow constitutes a highly heterogeneous population, as mentioned earlier [5]. 
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An alternative approach is to first centrifuge the bone marrow sample while employing a density 
gradient [31]. Percoll and Ficoll are commonly used density gradient solvents which can be used to 
clearly separate the mononuclear cells from the anuclear red blood cells.  Following centrifugation, 
the red blood cells will have collected at the bottom of the tube with the mononuclear cells, 
including the desired stem cells separated from them by a band of solvent. The procedure can be 
further enhanced through use of an antibody mixture, RosetteSep(R), which binds red blood cells to 
unwanted cell types causing them to be filtered to the bottom of the tube during centrifugation, 
thus further concentrating the desired cells in the sample. A potential problem with using density 
gradient centrifugation is that the VSEL stem cells, mentioned previously, can be lost from the 
mixture due to their small size [17]. 
Cell surface markers for bone marrow populations 
Stem cells usually exist in a very low concentration within a given tissue. In order to distinguish them 
from other cell populations, it is possible to exploit the cell surface markers which are unique for 
each cell type. These are proteins molecules, also known as “receptors” that coat the surface of all 
cells, and are able to bind to other cells, surfaces or proteins. They are used in vivo to signal other 
cells and to induce functionally significant cellular reactions, for example to stimulate production of 
a particular protein. As mentioned earlier, CD (cluster of differentiation) markers are commonly used 
to identify stem cell types in bone marrow, but additionally a number of antibody-binding receptors, 
antigens, can also be used. A selection of surface markers that have been reported for the isolation 
of bone marrow cells are shown in Table 1. It must also be considered that many different cell types 
may have a number of markers in common, so in order to isolate a specific stem cell populations 
contained within the highly heterogeneous bone marrow, or to further separate the sub-populations 
of the adherent fraction, a combination of different markers must be used. Therefore it is important 
not only to know the markers for the cell type that you wish to isolate, but also to be aware of the 
markers of the other cells contained in the bone marrow. 
Cell type Identifying markers References 
Mesenchymal 
stem cell 
(MSC) 
+ve 
CD13, CD29, CD44, CD54, CD55, CD59, 
CD73, CD90, CD105, CD106, CD166, CCR2 
(CD192), SB-10 (CD166), STRO-1, SB-10 
[32,33,34,35,36] 
-ve 
CD11b, CD14, CD19, CD31, CD34, CD45,  
CD79a, CD80, CD86, HLA-DR, vWF- 
Multipotent 
adult 
+ve 
CD13, CD90low, Flk-1low, Oct3/4, SSEA-1, 
VCAMlow, CD44low, MHC Ilow 
[37,38,39] 
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progenitor cell 
(MAPC) -ve 
CD34, CD45, CD117 (c-kit), MHC II, NANOG, 
CD44, MHC I (conflicting reports) 
Multipotent 
adult stem cell 
(MASC) 
+ve 
CD13, CD29, CD44, CD49a, CD49b, CD73, 
CD90, CD105, CCR2 (CD192), MHC I, CCR10, 
FGFR1, FGFR2, IL6ST, PDGFRA, PDGFRB, 
TGFBR1, TGFBR2 [40,36]  
-ve 
CD14, CD34, CD38, CD45, CD133, CD117 (c-
kit), HLA-DR 
Very small 
embryonic-like 
(VSEL) stem 
cell 
+ve 
CD34, AC133, c-Met, CXCR4AP, LIF-R, SSEA-
1 (mouse), SSEA-4 (human), 
[17] 
-ve 
CD29, CD45, CD90, CD105, Lin, HLA-DR, 
MHC I 
Table 1 - Characteristic markers for several non-hematopoietic stem cell types reported to have been found in bone 
marrow. Adapted from Ratajczak et al, 2008. 
Cell receptors must be “tagged” with the specific signalling molecules that they bind with in vivo in 
order to separate stem cell populations from within a heterogeneous tissue such as bone marrow. 
Further, these signalling molecules must be modified or attached to another particle or molecule, 
which can then be applied using some technique to either separate or merely distinguish the tagged 
cells. 
Most techniques for separating samples of stem cells from heterogeneous populations involve the 
use of surface markers in the attachment of either: 1) magnetic particles, allowing the user to 
separate the tagged population through the application of magnetic forces; or 2) fluorescent 
proteins or molecules so that cells can be isolated based on their light-scattering or fluorescence 
properties. Other separation techniques exist that fall outside these 2 main categories, and some 
will also be addressed in this review. Some of these techniques are shown in Figure 2. 
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Figure 2 – An overview of the separation techniques described in this chapter: (i) Magnetic-activated cell sorting 
(MACS®): in this case the desired cells (MSCs) expressing a specific antigen attach to an antibody-bound magnetic 
particle before being run through a magnetic separator column. The MSCs are shown to be retained on the column; (ii) 
Fluorescence-activated cells sorting (FACS): the sample, containing MSCs which have previously been tagged with a 
fluorescent marker, is injected into the system where the cells are hit by a laser. The resulting fluorescence and scatter 
data are detected by a computer, which then determines which are the cells of interest and causes a charge to be 
induced, allowing them to be finally separated using charged plates; (iii) Microfluidics/Lab-on-a-chip/Raman-activated 
cell sorting: a number of methods for separation or analyses of cell populations currently exist using this technology. 
One separation system involves placing the sample on the chip, and using different flow rates, cells could be isolated 
based on their ability to pass through channels of different sizes [41]; (iv) Field flow fractionation: a perpendicular field 
is applied to a flowing sample of the mixed population, which causes separation of the different cell types based on 
characteristic properties such as their size, shape and flexibility [42]. 
Magnetic separation systems 
Magnetic-activated cell sorting, MACS®, is the most commonly used method of sorting cells by 
magnetic forces, and is a registered trademark of Miltenyi Biotec GmbH (Bergisch Gladbach, 
Germany). Using this separation technique, the cells of interest are labelled with 50nm diameter, 
superparamagnetic beads and sorted using a packed column. Separation can be achieved by first 
coating the magnetic beads with an antibody, which is known to selectively bind to the desired cell 
type, and incubating them with the sample [43]. Once the cells have bound to the particles, the 
mixture is passed through a small column under the influence of a strong magnetic force. This 
induces a high gradient magnetic field in the column matrix, causing the particle-bound cells to be 
retained while the untagged cells pass through (see Figure 2). The column is washed with buffer to 
ensure no unwanted cells remain within the matrix, before the magnetic force is removed and the 
tagged cells can be eluted from the column. The magnetic beads can then be removed from the cells 
using enzymes. This separation system is quite flexible, and can be very quick depending on the 
8 
 
method of tagging the cells that is required. When only one labelling step is required to bind an 
antibody to the magnetic particle, i.e. if the cells can be directly attached via the antibody, then the 
entire separation may take as little as 30 minutes. However, it may not be possible to bind the cells 
and the beads directly, and an intermediary antibody, either biotinylated or fluorochrome-bound, 
for example, might be required instead. 
Above is a description of a technique for positively selecting the cells of interest. As discussed earlier, 
this is not always possible because there is significant overlap in the surface receptors expressed by 
different cells types. Therefore it may be necessary to employ different strategies using MACS in 
isolating the desired cells. For example, it may be preferable to bind magnetic particles to a 
significant population of unwanted cells, allowing the cells of interest to pass straight through the 
column, while many of the impurities remain bound. The desired cells can then be positively 
selected from the remaining mixture as before. There have been reports of MACS being used to 
isolate MSC populations from bone marrow [44,45,46], umbilical cord blood [45] and lipoaspirate 
samples [47]. Gronthos and Zannettino reported the use of the MACS system to isolate “bone 
marrow stromal stem cells” (BMSSC), a population of cells that display similar characteristics to 
MSCs. The STRO-1 antigen was the only marker used in the initial isolation with magnetic sorting, 
but the population was then further enriched using FACS. The CD106 marker was used to separate 
“STRO-1bright/CD106+” BMSSCs from the nucleated red cells and lymphocytes present in the STRO-1-
positive population [48]. 
Another magnetism-based separation system, the magnetic particle concentrator (MPC®; Dynal 
Bitoech.), has been used to isolate mesenchymal stem cells from murine bone marrow [30]. Three 
immunodepletion separations were performed using markers: CD11b, CD34 and CD45, which were 
bound with superparamagnetic “Dynabeads®” (Dynal Bitoech.). 
One of the key disadvantages of both FACS and MACS technology is that they require samples to be 
in single cell suspension considering, as mentioned previously, the initial purification of MSCs from 
bone marrow aspirate often involves allowing the MSCs, amongst other cells, to adhere to tissue 
culture plastic.  Given that enzymatic dissociation of adherent cells with, for example, trypsin, can 
lead to proteolytic damage of cell surface proteins, it is important that the method of cell harvesting 
is carefully considered when FACS or MACS is used for adherent cell purification.  Although MSCs can 
be harvested using an enzyme-free dissociation buffer, viability is lower than if trypsin is used [49], 
highlighting the need for purification methods which work in situ.  One such method is laser-
mediated cell purification.  Cyntellect (California, USA) have generated a laser-enabled analysis and 
processing (LEAPTM) platform which combines imaging capability with laser technology to purify cell 
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populations in situ in tissue culture well plates by eliminating unwanted cells by necrosis, apoptosis 
or cell lysis [50]. For instance, labelled HeLa cells were effectively removed from a monolayer of 
unlabelled HeLa cells, resulting in approximately 100% purity [51]. If MSCs could be distinguished 
from other bone marrow cell populations by brightfield imaging or by fluorescently marking the 
unwanted cells (ie negative selection), this technology could be used to damage and lift off 
unwanted cells which could then be washed away.   Potential issues might include the processing 
time for a tissue culture flask and yield of purified cells as Szaniszlo and colleagues showed a loss of 
10-20% of untargeted cells in their HeLa experiments, following laser treatment. Some optimisation 
of the system for use with MSCs may also be required because the need for lower cell densities at 
the time of treatment if the unwanted cells are present at higher than 5% of the population has also 
been reported [50,51], and this could be problematic with MSCs due to their low abundance, even 
within the adherent population. 
Optical separation systems  
Flow Cytometry 
The term cytometry describes the process by which the characteristics of single cells (or particles of 
a similar size) are measured [52]. There are many different forms of cytometry, each with their own 
unique features; however the most popular is undoubtedly flow cytometry, FC [53]. FC is an 
extremely powerful, high-throughput, diagnostic technique which can measure the physical and/or 
chemical characteristics of single cells as they pass individually through a laser beam [52,54,55]. 
Exposure to the laser beam causes light scattering in two planes, forward angle light scattering  and 
right angle light scattering , which provide information about the size and refractive properties of 
the cell [54].  More specific cell characteristics can then be determined through the use of 
fluorescent probes and multiparametric analysis can be performed. Flow cytometers also have the 
added ability to sort cells within a heterogeneous mixture (also known as a cell or flow sorter) based 
on the light scattering and fluorescence characteristics of the cells [52].  Such flow cytometers are 
referred to as fluorescence activated cell sorting (FACS) devices.  Exposure to the laser beam causes 
light scattering in two planes, forward angle light scattering (FALS) and right angle light scattering 
(RALS), which provide information about the size of the cell and refractive properties of the cell 
(Hewitt CJ, 2006; see Figure 3).  In addition to this, FC allows for multiparametric analysis which can 
be used to quantify cell constituent relationships [56]. 
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Figure 3 - Schematic of a typical flow cytometry instrument. A laser passes through a flowing sample of cells causing light 
to scatter, which is detected in two directions: 1) Forward angle light scatter (FALS), measured at 180
O
 to the beam; and 
2) Right angle light scatter (RALS), measured at 90
O
 to the laser. Photo multiplier tubes (PMT) are used to measure light 
emitted due to fluorescent tags on cells of interest, also at 90
O
 from the angle of the laser. From Hewitt & Von-Caron, 
2004. 
FACS technology has been used to purify MSCs from heterogeneous cell populations based on the 
positive identification of cell surface markers expressed by MSCs [35].  For example FACS has been 
used to  identify and isolate MSC subsets from bone marrow [57] and CD9+, CD90+ and CD166+ 
mesenchymal progenitors from synovial membranes of osteoarthritic patients [58].   Initially sorting 
cells by FACS was quite time consuming, however, high speed sorters are now available and with 
continuing advances in instrumentation and software (recently reviewed in Preffer & Dombkowski, 
2009), the use of FACS in the MSC field is likely to grow. 
One of the main disadvantages associated with using FACS in the stem cell field, however, is our 
current lack of knowledge of specific or unique cell markers for cell types such as MSCs and so a 
complex regime of positive and negative selection may need to be used to isolate the cells of 
interest. Other disadvantages are thought to include an altered cell viability and/or function as a 
result of the probes used (through both their physical interaction and in the washing protocols used 
which may result in the loss of cells), physical stresses exerted on the cells by flowing through the 
nozzle, laser damage and osmotic stress and potential contamination of cells.  However, since cells 
are measured and sorted on an individual basis using filtered (0.2µm) sheath fluid the latter is 
probably unlikely.  Despite these perceived drawbacks, there are several reports in which stem cells 
or stem cell-derived cells survived and have been cultured successfully in vitro without 
11 
 
contamination for up to 6 weeks or have even been transplanted into an animal model [59,60,61]. 
New models of FACS machines also exist which can be operated inside a biological safety cabinet 
thereby lowering the risk of contamination. The iCyt Reflection Cell Sorter (iCyt, Illinois, USA) system 
is one example, and is capable of not only preventing contamination of the cells but also reducing 
the biohazard associated with using cells in an open system. Generally speaking, these new FACS 
instruments remain expensive, are currently only used for analytical, lab-scale purposes [62] and are 
unlikely to be suitable for large scale separations. 
Other Techniques 
Field-flow fractionation 
This family of techniques is based on separation occurring by differential retention of analytes 
(ranging from proteins to whole cells) in a fluid stream flowing through a very thin, empty channel 
with a field applied in a perpendicular direction, but there are many variants [42].  It has the ability 
to sort cells based on biophysical properties, such as cell size, shape, flexibility, membrane 
roughness, and has previously been used to sort mammalian cells such as red blood cells [42].  More 
recently it was reported that this technique could even detect distinct fractionation profiles of MSCs 
from different tissue sources and it was able to accurately separate MSCs from epithelial cells [63]. 
The advantages of this system include that it could be used to isolate cells which are not well 
characterised in terms of cell surface markers, it is biocompatible, relatively low cost and  could be 
scaled up, making it an attractive method to pursue in the stem cell field.   
Antibody-column 
A method of separating cell populations has been described by Mahara & Yamoaka, whereby CD34-
positive cells were bound to a cell rolling column containing immobilized anti-CD34-antibodies [64]. 
The column surface was activated using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (WSC) and filled with a solution of the mouse anti-human CD34 antibody. A cell 
suspension containing CD34-positive KG-1a, and CD34-negative HL-60 cells was injected by syringe 
at a constant rate of 50µL/min, with the column tilted at an angle. Phosphate-buffered saline (PBS) 
was also washed through the column to promote cell rolling. The authors of the study claim the 
system to be superior to MACS in that it is capable of separating cells based on their surface marker 
density, due to the additional cell rolling [64]. They also indicated their belief that this system would 
prove quicker and less damaging than other separation techniques, as well as producing a highly 
pure population of cells. The system was considered a potential application for the separation of 
bone marrow MSCs in this study. 
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Microfluidic Technology 
Microfluidic (MF) or lab-on-a-chip (LOC) techniques fall under the area of nanotechnology, however 
in recent years, both MF and LOC techniques have been developed and utilised for the investigation 
of biological phenomena, with the cell being at the crux of the investigations [65]. MF or LOC devices 
allow for not only the analysis of single cells, but also provide a platform for cell culture and can 
integrate and automate cell manipulation with detection techniques [65]. Although MF and LOC 
have not been employed for the separation of MSCs from bone marrow, MF has been applied to 
amniotic fluid MSCs. The cells were isolated based on their size and the sample flow rate, and as a 
result, their ability to pass through differently-sized microfluidic channels. An initial separation 
efficiency of MSCs of 82.8% was achieved, but with repeated cycling, it was increased to 97.1% [41]. 
Raman activated cell sorting (RACS) 
Microfluidic technologies are being extended for use in novel cell sorting techniques, an example of 
which being the recently developed integrated optofluidic Raman activated cell sorting platform, 
which was created in California, USA [66]. This system is based on laser tweezers Raman 
spectroscopy which uses a laser beam to both optically trap individual cells and as an excitation 
source to generate a Raman spectrum or fingerprint.  By integrating this with a multichannel 
microfluidics device it allows for automated delivery of cells to the laser trap and sorting of the cells 
based on their fingerprint.  Whilst still very much in its infancy, more proof-of-principle work has 
shown that using Raman microspectroscopy with hESCs, human foetal left ventricular 
cardiomyocytes and hESC-derived cardiomyocytes each have a Raman fingerprint and that therefore 
RACS could potentially be employed as a non-destructive, label-free sorting method in stem cell 
science [67].  At the moment the systems’ throughput and efficiency are low compared to an 
established system like FACS but it may prove useful in instances where unique cell markers cannot 
be identified or when investigating cells which may become altered or activated upon antibody 
binding to its surface markers. 
Conclusions 
The ultimate goal of separating the constituent cell populations in bone marrow is the identification 
of the multiple phenotypes present within the mixed marrow community, potentially for use in 
clinical therapies. These cell populations are small in number and show diversity in their origins and 
differentiation capability. This presents a major challenge for the methodologies that have been 
developed for isolation and separation. In addition, the identification of a ‘true’ pluripotent stem 
cell, which is capable of continuous division and differentiation into the three germ layers, is a 
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difficult task due to the very small populations present in the marrow and the fact that the markers 
that truly indicate these traits are yet to be fully understood. 
This review outlines the markers which have been identified for the isolation of different fractions 
from within a bone marrow sample, including MSCs. Routine approaches for large scale 
identification have been put into practice for isolating stromal and haematopoietic populations, 
while other markers for many of the sub-populations are still being defined. Technologies which 
have been developed for the isolation of stem cell populations within bone marrow range from 
magnetic to optical to microfluidic techniques. Current research includes developing single cell 
technologies for isolating and defining low numbers of ‘stem’ cell populations which can form cloned 
stock populations for allogeneic therapies.  These technologies form an important basis for 
ultimately bringing cell therapies to the clinic for treatment of a variety of diseases. 
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